CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply. Issue 1 (January 2022)

Record Type:: Journal Article
Title:: CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply. Issue 1 (January 2022)
Main Title:: CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply
Authors:: Fennell, Dean A
Griffiths, Gareth
Ottensmeier, Christian
Hanna, Gerard G
Danson, Sarah
Szlosarek, Peter
Nye, Mavis
Abstract:
Is Part Of:: Lancet oncology. Volume 23:Issue 1(2022)
Journal:: Lancet oncology
Issue:: Volume 23:Issue 1(2022)
Issue Display:: Volume 23, Issue 1 (2022)
Year:: 2022
Volume:: 23
Issue:: 1
Issue Sort Value:: 2022-0023-0001-0000
Page Start:: e14
Page End:: e15
Publication Date:: 2022-01
Subjects:: Oncology -- Periodicals
Neoplasms -- Periodicals
Cancérologie -- Périodiques
Oncologie
Oncology
Periodicals
Electronic journals
616.994005
Journal URLs:: http://www.sciencedirect.com/science/journal/14702045 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S1470-2045(21)00722-1 ↗
Languages:: English
ISSNs:: 1470-2045
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5146.090000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 20403.xml